Login
$RCKT
$2.19 +$0.03 (1.39%) After hours

$RCKT SEC Filings

Filed On Filing
13 Nov 2026 144
13 Nov 2026 144
12 Nov 2026 Form 4: Chaudhuri Sarbani, See Remarks

Sold 4,872 shares ($11.3K)

12 Nov 2026 8-K: Results of Operations and Financial Condition

FDA alignment establishes path to complete the pivotal Phase 2 trial of RP-A501 in Danon disease; dosing completion expected by mid-2027

12 Nov 2026 10-Q
09 Nov 2026 Form 4: Wilson Martin, General Counsel

Sold 53,389 shares ($128K)

09 Nov 2026 144
09 Nov 2026 144
05 Nov 2026 144
30 Oct 2026 SCHEDULE 13G/A
06 Oct 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +2 more

THIS LOAN AND SECURITY AGREEMENT is made and dated as of September 30, 2026, and is entered into by and among ROCKET PHARMACEUTICALS, INC., a Delaware corporation (“Company”), its Subsidiaries SPACECRAFT SEVEN, LLC, a Delaware limited li...

15 Sep 2026 Form 4: Wilson Martin, General Counsel

Sold 75,364 shares ($256K)

15 Sep 2026 144
15 Sep 2026 8-K: Regulation FD Disclosure

FDA confirms pivotal efficacy population of 12 patients, including the first three treated under the modified protocol

14 Sep 2026 144
11 Sep 2026 144
11 Sep 2026 144
02 Sep 2026 25-NSE
27 Aug 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

20 Aug 2026 Form 4: Wilson Martin, General Counsel

Sold 631 shares ($2.13K)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support